Involvement of non-opioid peptides in the pathogenesis of neurological and psychiatric disorders: evidence from CSF and post-mortem studies.

Charles Nemeroff, G. Bissette

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In the past twenty years, more than thirty peptides have been discovered to be present in the mammalian central nervous system (CNS). As the neuroanatomical distribution, neurochemical, electrophysiological and pharmacobehavioral effects of this novel group of neuroregulators have been described, it is evident that certain of these peptide-containing neural circuits may be pathologically altered in neuropsychiatric disorders. Although much attention has been focused on the opioid peptides, substantial data strongly support the hypothesis that non-opioid peptides such as somatostatin, neurotensin and substance P are altered in a diverse number of neuropsychiatric disorders including Alzheimer's disease, Huntington's chorea, Parkinson's disease, major depression and schizophrenia.

Original languageEnglish
Pages (from-to)333-341
Number of pages9
JournalProgress in Clinical and Biological Research
Volume192
StatePublished - Dec 1 1985
Externally publishedYes

Fingerprint

Nervous System Diseases
Psychiatry
Peptides
Neurotensin
Opioid Peptides
Huntington Disease
Substance P
Somatostatin
Neurotransmitter Agents
Parkinson Disease
Schizophrenia
Alzheimer Disease
Central Nervous System
Depression

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{67fb1123d8f64d6e930661ed995c6fe4,
title = "Involvement of non-opioid peptides in the pathogenesis of neurological and psychiatric disorders: evidence from CSF and post-mortem studies.",
abstract = "In the past twenty years, more than thirty peptides have been discovered to be present in the mammalian central nervous system (CNS). As the neuroanatomical distribution, neurochemical, electrophysiological and pharmacobehavioral effects of this novel group of neuroregulators have been described, it is evident that certain of these peptide-containing neural circuits may be pathologically altered in neuropsychiatric disorders. Although much attention has been focused on the opioid peptides, substantial data strongly support the hypothesis that non-opioid peptides such as somatostatin, neurotensin and substance P are altered in a diverse number of neuropsychiatric disorders including Alzheimer's disease, Huntington's chorea, Parkinson's disease, major depression and schizophrenia.",
author = "Charles Nemeroff and G. Bissette",
year = "1985",
month = "12",
day = "1",
language = "English",
volume = "192",
pages = "333--341",
journal = "Progress in Clinical and Biological Research",
issn = "0361-7742",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Involvement of non-opioid peptides in the pathogenesis of neurological and psychiatric disorders

T2 - evidence from CSF and post-mortem studies.

AU - Nemeroff, Charles

AU - Bissette, G.

PY - 1985/12/1

Y1 - 1985/12/1

N2 - In the past twenty years, more than thirty peptides have been discovered to be present in the mammalian central nervous system (CNS). As the neuroanatomical distribution, neurochemical, electrophysiological and pharmacobehavioral effects of this novel group of neuroregulators have been described, it is evident that certain of these peptide-containing neural circuits may be pathologically altered in neuropsychiatric disorders. Although much attention has been focused on the opioid peptides, substantial data strongly support the hypothesis that non-opioid peptides such as somatostatin, neurotensin and substance P are altered in a diverse number of neuropsychiatric disorders including Alzheimer's disease, Huntington's chorea, Parkinson's disease, major depression and schizophrenia.

AB - In the past twenty years, more than thirty peptides have been discovered to be present in the mammalian central nervous system (CNS). As the neuroanatomical distribution, neurochemical, electrophysiological and pharmacobehavioral effects of this novel group of neuroregulators have been described, it is evident that certain of these peptide-containing neural circuits may be pathologically altered in neuropsychiatric disorders. Although much attention has been focused on the opioid peptides, substantial data strongly support the hypothesis that non-opioid peptides such as somatostatin, neurotensin and substance P are altered in a diverse number of neuropsychiatric disorders including Alzheimer's disease, Huntington's chorea, Parkinson's disease, major depression and schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=0022333186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022333186&partnerID=8YFLogxK

M3 - Article

C2 - 2934745

AN - SCOPUS:0022333186

VL - 192

SP - 333

EP - 341

JO - Progress in Clinical and Biological Research

JF - Progress in Clinical and Biological Research

SN - 0361-7742

ER -